Nie Song, McDermott Sean P, Deol Yadwinder, Tan Zhijing, Wicha Max S, Lubman David M
Department of Surgery, University of Michigan, Ann Arbor, MI, USA.
Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA.
Proteomics. 2015 Nov;15(22):3772-83. doi: 10.1002/pmic.201500002. Epub 2015 Oct 7.
Accumulating evidence has demonstrated that breast cancers are initiated and develop from a small population of stem-like cells termed cancer stem cells (CSCs). These cells are hypothesized to mediate tumor metastasis and contribute to therapeutic resistance. However, the molecular regulatory networks responsible for maintaining CSCs in an undifferentiated state have yet to be elucidated. In this study, we used CSC markers to isolate pure breast CSCs fractions (ALDH+ and CD44+CD24- cell populations) and the mature luminal cells (CD49f-EpCAM+) from the MCF7 cell line. Proteomic analysis was performed on these samples and a total of 3304 proteins were identified. A label-free quantitative method was applied to analyze differentially expressed proteins. Using the criteria of greater than twofold changes and p value <0.05, 305, 322 and 98 proteins were identified as significantly different in three pairwise comparisons of ALDH+ versus CD44+CD24-, ALDH+ versus CD49f-EpCAM+ and CD44+CD24- versus CD49f-EpCAM+, respectively. Pathway analysis of differentially expressed proteins by Ingenuity Pathway Analysis (IPA) revealed potential molecular regulatory networks that may regulate CSCs. Selected differential proteins were validated by Western blot assay and immunohistochemical staining. The use of proteomics analysis may increase our understanding of the underlying molecular mechanisms of breast CSCs. This may be of importance in the future development of anti-CSC therapeutics.
越来越多的证据表明,乳腺癌起源于一小群被称为癌症干细胞(CSCs)的干细胞样细胞,并由其发展而来。据推测,这些细胞介导肿瘤转移并导致治疗抗性。然而,负责维持CSCs处于未分化状态的分子调控网络尚未阐明。在本研究中,我们使用CSC标志物从MCF7细胞系中分离出纯的乳腺CSCs组分(ALDH+和CD44+CD24-细胞群体)以及成熟的腔上皮细胞(CD49f-EpCAM+)。对这些样本进行了蛋白质组学分析,共鉴定出3304种蛋白质。采用无标记定量方法分析差异表达的蛋白质。使用变化大于两倍且p值<0.05的标准,在ALDH+与CD44+CD24-、ALDH+与CD49f-EpCAM+以及CD44+CD24-与CD49f-EpCAM+的三次两两比较中,分别鉴定出305、322和98种蛋白质有显著差异。通过Ingenuity Pathway Analysis(IPA)对差异表达蛋白质进行通路分析,揭示了可能调控CSCs的潜在分子调控网络。通过蛋白质印迹分析和免疫组织化学染色对选定的差异蛋白质进行了验证。蛋白质组学分析的应用可能会增加我们对乳腺CSCs潜在分子机制的理解。这在抗CSC治疗的未来发展中可能具有重要意义。